Home > Newsletters > FDAnews Drug Daily Bulletin > Boxed Warning Added to Plavix Highlights Metabolism Issues
FDAnews Drug Daily Bulletin
March 24, 2010 | Vol. 7 No. 58
Boxed Warning Added to Plavix Highlights Metabolism Issues
Sanofi-Aventis and Bristol-Myers Squibb’s blockbuster anti-clotting drug Plavix will now carry a boxed warning about the drug’s ineffectiveness in some patients with a genetic mutation. The warning also advises healthcare professionals that genetic tests are available to identify patients whose bodies can’t metabolize Plavix (clopidogrel bisulfate) well, and other anti-platelet medications should be used for those patients, the FDA says.
Washington Drug Letter
ePublishing :: CMS, Hosting & Web Development | © Copyright by FDAnewsAll rights reserved. Do not duplicate or redistribute in any form.